GYLDEN PHARMA LIMITED
Research and experimental development on biotechnology
GYLDEN PHARMA LIMITED
Research and experimental development on biotechnology
Previous Company Names
Contact & Details
Contact
Registered Address
4 & 5 Dunmore Court Wootton Road Abingdon Oxfordshire OX13 6BH England
Full company profile for GYLDEN PHARMA LIMITED (09955881), an active life sciences and medical technology company based in Abingdon, England. Incorporated 18 Jan 2016. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.
Business Summary
This company specializes in providing innovative solutions and services across multiple sectors. Sign up to viewReports
Credit Report
In-depth credit score, financial analysis, risk assessment and company intelligence.
Financials
Financials
Net Assets, Total Assets & Total Liabilities (2020–2024)
Cash in Bank
£294.38k
Net Assets
-£3.34M
Total Liabilities
£5.28M
Turnover
N/A
Employees
36
Debt Ratio
272%
Financial History
Revenue, profit, EBITDA and key financial figures
2025 31 Mar Year End | 2024 31 Mar Year End | |
|---|---|---|
| P&L | ||
| Revenue | ||
| Gross Profit | ||
| Operating Profit | ||
| Net Profit | ||
| EBITDA | ||
| Assets | ||
| Cash | ||
| Total Assets | ||
| Liabilities | ||
| Total Liabilities | ||
| Key Metrics | ||
| Employees | ||
Funding
Fundraising & Grants
See all 5 funding rounds
Sign up to view complete fundraising history
Investors (5)
| Investor Name | Investor Since | Participating Rounds |
|---|---|---|
| Investor 1 | Jan 2022 | Series A |
| Investor 2 | Jan 2022 | Series A |
| Investor 3 | Jan 2022 | Series A |
See all 5 investors
Sign up to view complete investor information
Officers
Officers
| Status | |||||
|---|---|---|---|---|---|
| Chia, Dr Poh Hui | Director | Singaporean | Singapore | 5 Jan 2024 | Active |
| Jackson, David Clifford | Director | British | England | 17 Aug 2022 | Active |
See all 17 officers
Sign up to view the full officer history
Persons with Significant Control
Persons with Significant Control (1)
Professor Thomas William Rademacher
American
- Significant Influence Or Control
Group Structure
Group Structure
Charges
Charges
Properties
Properties
No related properties
Documents
Company Filings
| Date | Category | Description | Document |
|---|---|---|---|
| 12 May 2026 | Capital | Allotment of shares (GBP 45.037426) on 11 May 2026 | |
| 4 Feb 2026 | Confirmation Statement | Confirmation statement made on 7 Aug 2025 with updates | |
| 2 Jan 2026 | Officers | Appointment of Mr Frank Tufaro as director | |
| 31 Dec 2025 | Accounts | Annual accounts made up to 31 Mar 2025 | |
| 30 Dec 2025 | Officers | Termination of Sergio Pagani as director on 14 Nov 2025 |
Allotment of shares (GBP 45.037426) on 11 May 2026
Confirmation statement made on 7 Aug 2025 with updates
Appointment of Mr Frank Tufaro as director
Annual accounts made up to 31 Mar 2025
Termination of Sergio Pagani as director on 14 Nov 2025
Recent Activity
Latest Activity
Allotment of shares (GBP 45.037426) on 11 May 2026
3 weeks ago on 12 May 2026
Confirmation statement made on 7 Aug 2025 with updates
4 months ago on 4 Feb 2026
Appointment of Mr Frank Tufaro as director
5 months ago on 2 Jan 2026
Annual accounts made up to 31 Mar 2025
5 months ago on 31 Dec 2025
Termination of Sergio Pagani as director on 14 Nov 2025
5 months ago on 30 Dec 2025